EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery.

EGFR-targeting antibody-drug conjugate SYS6010 shows promise in advanced solid tumors, marking a shift from kinase inhibition to antigen-guided therapy.

• Why it matters: This approach addresses limitations of traditional EGFR inhibitors by directly delivering cytotoxic agents to tumor cells, potentially improving treatment efficacy in cancers like non-small cell lung cancer.
• What they did: Li et al. conducted a first-in-human phase 1 trial of SYS6010, an antibody-drug conjugate targeting EGFR, in patients with advanced solid tumors, exploring its safety and potential benefits.
• The result: The study demonstrates the feasibility of antigen-guided drug delivery, paving the way for more targeted and effective therapies in EGFR-expressing cancers.